文献速递慢病管理预防保健、筛查与疫苗

地舒单抗与口服双膦酸盐对骨质疏松成人2型糖尿病发生率的影响:基于人群的队列研究

Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study.
PubMed 文献 · BMJ · 2023-04-18

该研究基于英国初级保健数据库模拟随机对照试验,纳入45岁及以上使用地舒单抗或口服双膦酸盐治疗骨质疏松的成人。

要点

  • 地舒单抗相比口服双膦酸盐与2型糖尿病风险降低相关(HR 0.68)。
  • 糖尿病前期患者使用地舒单抗获益可能更明显(HR 0.54)。
  • 地舒单抗组2型糖尿病发病率为5.7/1000人年,低于口服双膦酸盐组的8.3/1000人年。

核心结论

  • 在骨质疏松成人中,地舒单抗使用与口服双膦酸盐使用相比,2型糖尿病发生风险更低。
  • 该研究提供人群水平证据,提示地舒单抗可能对糖代谢有额外益处。

研究设计与样本

  • 基于人群的研究,利用电子健康记录模拟随机目标试验。
  • 数据来自英国IQVIA医学研究数据初级保健数据库,1995-2021年。
  • 研究对象为45岁及以上使用地舒单抗或口服双膦酸盐治疗骨质疏松的成人。

主要发现

  • 地舒单抗组2型糖尿病发病率为5.7(95%CI 4.3-7.3)/1000人年,口服双膦酸盐组为8.3(95%CI 7.4-9.2)/1000人年。
  • 地舒单抗起始与2型糖尿病风险降低相关(HR 0.68,95%CI 0.52-0.89)。
  • 糖尿病前期患者使用地舒单抗的HR为0.54(95%CI 0.35-0.82)。
  • 体重指数≥30者使用地舒单抗的HR为0.65(95%CI 0.40-1.06)。

关键数值与推荐

  • 2型糖尿病主要结局采用诊断代码定义。
  • 采用Cox比例风险模型估计调整风险比和95%置信区间,以as treated方法比较地舒单抗与口服双膦酸盐。

临床怎么用

  • 对于骨质疏松成人,选择地舒单抗而非口服双膦酸盐时,可考虑其潜在的2型糖尿病风险降低益处,尤其糖尿病前期患者。
  • 临床决策需结合患者个体情况,该研究结果支持地舒单抗在糖代谢方面的额外获益可能。

局限性

  • 研究为观察性设计,尽管模拟目标试验,仍可能存在残余混杂。
  • 2型糖尿病基于诊断代码定义,可能存在错分。
  • 平均随访2.2年,长期效应未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the effect of denosumab compared with oral bisphosphonates on reducing the risk of type 2 diabetes in adults with osteoporosis. DESIGN: Population based study involving emulation of a randomized target trial using electronic health records. SETTING: IQVIA Medical Research Data primary care database in the United Kingdom, 1995-2021. PARTICIPANTS: Adults aged 45 years or older who used denosumab or an oral bisphosphonate for osteoporosis. MAIN OUTCOME MEASURES: The primary outcome was incident type 2 diabetes, as defined by diagnostic codes. Cox proportional hazards models were used to estimate adjusted hazard ratios and 95% confidence intervals, comparing denosumab with oral bisphosphonates using an as treated approach. RESULTS: 4301 new users of denosumab were matched on propensity score to 21 038 users of an oral bisphosphonate and followed for a mean of 2.2 years. The incidence rate of type 2 diabetes in denosumab users was 5.7 (95% confidence interval 4.3 to 7.3) per 1000 person years and in oral bisphosphonate users was 8.3 (7.4 to 9.2) per 1000 person years. Initiation of denosumab was associated with a reduced risk of type 2 diabetes (hazard ratio 0.68, 95% confidence interval 0.52 to 0.89). Participants with prediabetes appeared to benefit more from denosumab compared with an oral bisphosphonate (hazard ratio 0.54, 0.35 to 0.82), as did those with a body mass index ≥30 (0.65, 0.40 to 1.06). CONCLUSIONS: In this population based study, denosumab use was associated with a lower risk of incident type 2 diabetes compared with oral bisphosphonate use in adults with osteoporosis. This study provides evidence at a population level that denosumab may have added benefits for glucose metabolism compared with oral bisphosphonates.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Lyu H, Zhao SS, Zhang L, et al. Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study. BMJ. 2023. PMID: 37072150. doi:10.1136/bmj-2022-073435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。